Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-centre, randomised, double-blind, placebo-controlled, phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects

Next Previous
Trial Profile

A single-centre, randomised, double-blind, placebo-controlled, phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALKS 7119 (Primary)
  • Indications Agitation
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Alkermes plc

Most Recent Events

  • 10 Jan 2022 Status changed from recruiting to completed as per results published in the British Journal of Clinical Pharmacology
  • 10 Jan 2022 Results published in the British Journal of Clinical Pharmacology
  • 28 Apr 2016 Full results from this study, including unblinded safety data, are expected in the second half of 2016, according to an Alkermes media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top